Trial Profile
Real world study from the CHAMP-HF registry comparing Entresto (sacubitril/valsartan) patients to patients not taking Entresto
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Dec 2021
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Chronic heart failure
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals Corporation
- 15 Nov 2021 Results (n=2092) assessing association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction presented at the American Heart Association Scientific Sessions 2021
- 18 Nov 2019 Results (n=4970) assessing HRQL and outcomes by Diabetes Mellitus status were presented at the American Heart Association Scientific Sessions 2019
- 18 Nov 2019 Results presented at the American Heart Association Scientific Sessions 2019